AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01332955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: (weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
Study NCT03706456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Darvadstrocel
Description: Darvadstrocel cell suspension for intralesional injection.
Study NCT03624972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual and Menopausal Health Resources
Description: Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal \& sexual health clinic.
Study NCT00928304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben (BAY94-9172)
Description: 300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
Study NCT03581799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral dispersible tablet
Description: Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
Study NCT03246711 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fasting
Description: Totally or partially fasting the holy month of ramadan for muslims
Study NCT01936597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic and preventive strategies
Description: Single set (control Arm)
Study NCT01936597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic and preventive strategies
Description: Controller
Study NCT01936597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic and preventive strategies
Description: Audio
Study NCT03899571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Oral Capsule for 5 days post-exposure
Description: Patients will receive oseltamivir for 5 days after last influenza exposure.
Study NCT01392768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
Study NCT01392768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
Study NCT02031757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perturbation training
Description: training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
Study NCT03899571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Oral Capsule for 10 days post-exposure
Description: Patients will receive oseltamivir for 10 days after last influenza exposure.
Study NCT00316849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT00316849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00316849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT00316849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT00316849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00316849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT03889444 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone intravitreal implant
Description: Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
Study NCT00598988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional Chinese acupuncture
Description: 10 treatments over 6 weeks
Study NCT00598988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical care
Description: standard care as provided by primary physician
Study NCT01202292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral (e.g., Psychotherapy, Lifestyle Counseling)
Description: Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
Study NCT03054441 — intervention group
Intervention type: OTHER
Intervention: Actigraph
Description: Actigraphs worn on wrists
Study NCT02962284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate with Methylprednisolone
Description: YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
Study NCT03259269 — intervention group
Intervention type: OTHER
Intervention: This is a non-intervention observational study
Description: No applicable intervention; this is a secondary data analysis observational study.
Study NCT01365598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
Study NCT01365598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Primaquine
Description: Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
Study NCT01365598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
Study NCT02031757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance exercises
Description: specific exercises regularly used in rehabilitation aiming to improve balance
Study NCT04568876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension
Description: Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
Study NCT03238261 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemotherapy and concomitant radiotherapy
Description: Radiotherapy (teletherapy + high or low rate brachytherapy)
Study NCT04568876 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Standard Therapy
Description: Standard therapy established for individual patients
Study NCT04568876 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard therapy established for individual patients
Study NCT01651234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCC-4401
Description: * Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg GCC-4401C~ * Cohort 2: 5.0-mg GCC-4401C~ * Cohort 3: 10-mg GCC-4401C~ * Cohort 4: 20-mg GCC-4401C~ * Cohort 5: 40-mg GCC-4401C~ * Cohort 6: 80-mg GCC-4401C
Study NCT01651234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GCC-4401C
Description: * Capsule, identical in appearance to GCC-4401C, for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg matching placebo~ * Cohort 2: 5.0-mg matching placebo~ * Cohort 3: 10-mg matching placebo~ * Cohort 4: 20-mg matching placebo~ * Cohort 5: 40-mg matching placebo~ * Cohort 6: 80-mg matching placebo
Study NCT00736606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: One single dose of 40mg
Study NCT00736606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 + simvastatin
Description: AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
Study NCT00126425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-mIBG (meta-iodobenzylguanidine)
Description: Single dose
Study NCT01102959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photographic Educational Material
Description: Photographic Educational Material on Carbohydrate Counting
Study NCT02784275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z
Study NCT02784275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00970060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
Study NCT03207230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardea SOLO
Description: Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
Study NCT03207230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraph wGT3X-BT
Description: Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
Study NCT03207230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wavelet Wristband
Description: Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
Study NCT03194607 — intervention group
Intervention type: OTHER
Intervention: Functional walk tests
Study NCT03194607 — intervention group
Intervention type: OTHER
Intervention: 3D analysis of locomotion and posture
Study NCT03194607 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Study NCT03890601 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: A single 15 mL blood draw is planned for this study, as follow:~* 10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~* 5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1.
Study NCT05824793 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A-PRF+
Description: A-PRF+ contributes to accelerating the healing process, more rapid revascularization, and reducing the risk of inflammation at the graft site. It leads to a decrease in the severity of postoperative complications. Many authors have mentioned platelet concentrates as an effective adjunction that improves the healing of hard and soft tissue and decreases pain, swelling, and trismus. However, there are still some controversial results in the literature. Recently, it has been demonstrated that the production of PRF with lower centrifugal force and lower centrifugal time has more potential to release several growth factors and facilitate more favorable healing at the site of the application when compared to standard PRF. Promoting the healing process after tooth extraction using A-PRF+ aims to manage patient discomfort as well as postoperation complications.
Study NCT04528381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: Laparoscopic orchiopexy
Study NCT01525745 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiosurgery/SBRT
Description: 1, 3 or 5 SBRT treatments
Study NCT01525745 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: 10 consecutive days of standard radiation
Study NCT01455155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative therapy (art and music therapy)
Description: Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.
Study NCT01455155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
Study NCT00565240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marvelon
Description: oral contraceptive
Study NCT00565240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuvaring
Description: contraceptive vaginal ring
Study NCT00565240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase Inhibitors
Study NCT02779530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 50 mg po, b.i.d for 6 days
Study NCT02779530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po, b.i.d. for 6 days
Study NCT03649815 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: App4Independence
Description: The mobile, app-based platform was designed to:~* Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement~* Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises)~* Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness~* Provide basic health/safety functionality and track level of wellness~* Provide an anonymous peer-peer online network for strategy sharing~* Provide an ambient sound detector to assist with identifying hallucinations
Study NCT01061840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™
Description: Patients will be treated once a month as long as sufficient material is available for up to 12 doses
Study NCT03238261 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy and concomitant radiotherapy
Description: Radiotherapy (teletherapy + high or low rate brachytherapy)
Study NCT01905462 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Analyses of data collected within the CPRD GOLD database.
Study NCT01905462 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cervarix
Description: Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
Study NCT01296646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg oral naltrexone once/day
Study NCT01296646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brenda Therapy Sessions
Description: participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
Study NCT01296646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: An inactive pill to control for non-pharmacological responses.
Study NCT00209742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFT
Description: P.O. everyday
Study NCT00209742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT
Description: P.O. everyday
Study NCT00209742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: USEL/Leucovorin
Description: P.O. everyday
Study NCT00209742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USEL/Leucovorin
Description: P.O. everyday
Study NCT01833390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HXe MRI lung ventilation
Description: MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
Study NCT03638518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture 5 weeks treatment. 2 sessions a week (30 minutes each session)
Study NCT03638518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Core stability exercises programme. 2 sessions a week (30 minutes each session) during 5 weeks
Study NCT02774668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grab-and-Go meal plan
Description: The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.~The amount of weight loss caused by these two meal plans is not expected to differ.
Study NCT02774668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jump-Start meal plan
Description: The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ.
Study NCT00835276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg tablets
Description: 1 x 180 mg
Study NCT00835276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALLEGRA® 180 mg tablets
Description: 1 x 180 mg
Study NCT02126241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICaS guided CRT optimization
Description: 1. Baseline CO measurement by NICaS~2. AV delay optimization:~   1. AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~  2. The AV delay yielding the maximal CO, will be considered the optimal AV delay~  3. The device will be programmed using the optimal AV delay~3. VV delay optimization:~   1. After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~  2. The VV delay yielding the maximal CO, will be considered the optimal VV delay~  3. The device will be programmed using the optimal VV delay
Study NCT03304093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Nivolumab 3mg/kg every 2 weeks
Study NCT00776191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physioneal 35
Description: Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
Study NCT00776191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physioneal 40
Description: Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
Study NCT00584779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: CLcr:14-5 mL/min
Study NCT00584779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: CLcr: 29-15 mL/min
Study NCT00584779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Hemodialysis
Study NCT00584779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: CLcr: 29-30 mL/min
Study NCT01405027 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Educational Intervention
Description: Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
Study NCT01405027 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient education and management skills training
Description: Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
Study NCT02089867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ezetimibe + plant sterols
Description: The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
Study NCT02089867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
Study NCT02089867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols
Description: The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks